Integra LifeSciences (NASDAQ:IART) Updates FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.410-2.510 for the period, compared to the consensus earnings per share estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its FY25 guidance to $2.41 to $2.51 EPS.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded down $0.40 during mid-day trading on Thursday, hitting $23.21. The stock had a trading volume of 223,228 shares, compared to its average volume of 600,608. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a 50 day moving average of $23.74 and a two-hundred day moving average of $21.84. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $41.17. The firm has a market cap of $1.79 billion, a PE ratio of -255.92, a PEG ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same period in the prior year, the firm earned $0.89 EPS. The firm’s revenue was up 11.5% on a year-over-year basis. Research analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on IART shares. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Hold” and an average price target of $23.00.

Insider Buying and Selling

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.10% of the stock is currently owned by corporate insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.